Every 8-K that Mainz Biomed NV (MYNZ) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MYNZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MYNZ filings page.
Quantum Cyber N.V. terminated its at-the-market issuance sales agreement with Maxim Group LLC, effective June 7, 2026, under the agreement’s terms. This arrangement, originally dated October 1, 2025 and amended May 4, 2026, allowed the company to sell shares into the market over time.
Before ending the program, Quantum Cyber sold 3,280,927 Ordinary Shares for net cash proceeds of about $4,388,515. The company states it will not owe any termination penalties, so ending the agreement does not trigger extra costs.
Quantum Cyber N.V. entered into Amendment No. 1 to its Intellectual Property License Agreement with BP United Inc., changing how their collaboration is structured. Instead of an exclusive supply agreement, BP United will provide manufacturing and consulting services, while the Company keeps the previously agreed $5,000,000 cash payment to fund ramp-up of its own manufacturing for Licensed Products.
The Consideration Shares become issuable at execution of the amendment and vest in four equal installments on September 30, 2026, March 31, 2027, June 30, 2027, and September 30, 2027. The filing also furnishes, under Regulation FD, a June 2026 corporate slide deck outlining Quantum Cyber’s autonomous defense platform, large target markets, patent portfolio, capital-light public structure with 22 shares outstanding, no debt and no warrants, and plans for a vertically integrated, NDAA‑aligned US manufacturing complex and contract-ready platforms supported by letters of intent with General Cherry and SOCOM.
Quantum Cyber N.V. reports that it has regained compliance with Nasdaq’s minimum bid price requirement. Nasdaq’s Listing Qualifications Department confirmed that for 10 consecutive business days, from May 13, 2026 to May 27, 2026, the closing bid price of the company’s ordinary shares was at or above $1.00 per share.
As a result, the company now meets Nasdaq Listing Rule 5550(a)(2), and Nasdaq has closed the matter that began with a prior notice on March 20, 2026 regarding failure to maintain the minimum bid price.
Quantum Cyber N.V. filed an extensive business update and reported that all remaining warrants were exercised, generating over $15 million in gross proceeds and leaving the company debt-free. Management plans to use the funds to expand research and development, build its commercialization team, and pursue strategic acquisitions for its autonomous defense and quantum-AI platforms.
The filing also details the company’s pivot from its prior diagnostics focus to an AI- and quantum-enabled autonomous systems business, including an IP license and commercial supply relationship with BP United Inc. Quantum Cyber highlights heavy reliance on defense and government customers, stringent export-control and AI/UAV regulations, and emerging quantum and counter‑UAS markets. Risk factors emphasize Nasdaq minimum bid-price non-compliance, substantial potential dilution from preferred shares convertible into hundreds of millions of ordinary shares, evolving AI and UAV regulation, cybersecurity threats, and the early, volatile state of quantum computing markets.
Quantum Cyber N.V. amended its Equity Distribution Agreement with Maxim Group LLC to raise the capacity of its at-the-market share offering program from $10,000,000 to up to $100,000,000 of ordinary shares.
The company also entered into a Consulting Agreement with Chief Financial Officer William Caragol, effective April 22, 2026. He will provide chief financial officer-level financial and accounting services for a monthly retainer of $20,000, with potential stock or option grants under the 2025 Omnibus Stock Plan at the board’s discretion. The consulting term runs through August 31, 2026 and may continue month to month, and either party can terminate with 30 days’ written notice.
Quantum Cyber N.V. reported completion of a private share sale that resulted in a change of control and broad boardroom changes. The company issued First Closing Shares for gross proceeds of $3 million on February 17, 2026 and had previously received $3 million as pre-payment for Second Closing Shares issued on April 22, 2026. These Second Closing Shares represented in excess of 90% of issued and outstanding ordinary shares on a fully diluted basis, and David E. Lazar became holder of over 95% of voting rights and the controlling shareholder. An Extraordinary General Meeting on April 22, 2026 approved all proposals, appointed David Natan and Avraham Ben‑Tzvi as directors, and coincided with the resignation of four prior directors and the Co‑Chief Executive Officer. The company also amended its Articles of Association while confirming its ordinary shares continue trading on the Nasdaq Capital Market under the symbol QUCY.
Mainz Biomed N.V. entered into an asset purchase agreement on April 9, 2026 to sell the intellectual property for its next generation colorectal cancer screening product candidates to an Italian buyer for $1.25 million. Closing is expected by April 23, 2026, subject to standard conditions and certain third-party consents, shipments and patent-related deadlines.
The company plans to use net proceeds to settle outstanding liabilities and for general corporate purposes. Management reiterates that winding down ColoAlert and next generation colorectal programs allows focus on a pancreatic cancer detection candidate and exploration of post-quantum cybersecurity opportunities.
Mainz Biomed previously reported stockholders’ equity of $641,600, below the $2.5 million minimum in Nasdaq Listing Rule 5550(b)(1). After receiving a total equity investment of $6 million in preferred shares in February and March 2026 and reducing monthly expenditures, the company believes its stockholders’ equity now exceeds $2.5 million and that it is currently in compliance with the Nasdaq listing requirement.
Mainz Biomed N.V. reported that Nasdaq has notified the company its ordinary shares no longer meet the minimum $1.00 bid price requirement, after trading below that level for 30 consecutive business days from February 5 to March 19, 2026. The company has 180 calendar days, until September 16, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for ten consecutive business days. If it does not regain compliance by then, it may qualify for an additional 180‑day period if it meets other initial listing standards and formally indicates an intention to cure, potentially via a reverse stock split. The notice has no immediate effect on the current Nasdaq listing, but failure to cure the deficiency could ultimately lead to delisting, which the company would have the right to appeal.
Mainz Biomed N.V., doing business as Quantum Cyber, reported a strategic update and fresh funding support. Shareholder David Lazar has pre-funded the second tranche of a previously announced private placement with $3,000,000, bringing his total investment under this commitment to $6,000,000, subject to customary closing conditions and shareholder approval for issuing series D and series E preferred stock.
The company is aligning its strategy with the Trump Administration’s new National Cybersecurity Strategy and is evaluating acquisition targets in quantum computing, post-quantum cryptography, zero-trust architecture, and related cyber defense areas. Management emphasizes that no definitive deals have been signed yet, and future transactions and the private placement remain dependent on required approvals and conditions.
Mainz Biomed N.V. has appointed Robert P. Liscouski as Chairman of its board of directors, with his term running until an extraordinary general meeting planned for April 2026. The company states there are no related-party arrangements or reportable transactions tied to his appointment.
The company also plans to change its name to Quantum Cyber and its Nasdaq ticker from “MYNZ” to “QUCY,” with trading under the new symbol beginning on March 12, 2026. The symbol change does not affect shareholder rights, and the CUSIP will remain the same. The company reiterates its focus on developing a pancreatic cancer screening business in the U.S. while evaluating a sale of its colorectal cancer screening assets and winding down its German subsidiary.
Mainz Biomed N.V. entered into a private placement with investor David Lazar for 6.0 USD million of convertible non-redeemable preferred stock, funded in two tranches of 3.0 USD million each. The first 3.0 USD million closed at 1.00 USD per preferred share; the second 3.0 USD million is expected after stockholder approvals at 1.50 USD per preferred share.
The preferred shares are highly dilutive: upon full conversion after required approvals, the First Closing Shares would represent about 55.4% and the Second Closing Shares about 90.2% of issued and outstanding ordinary shares on a fully diluted basis, or roughly 95.6% combined. Until conversion approval, a 19.99% beneficial ownership cap applies.
Net proceeds are earmarked for operations, working capital, and addressing liabilities. The company plans to focus on its U.S. pancreatic cancer detection program, explore sales of colorectal cancer screening assets, and wind down its German subsidiary. David Lazar was appointed Chair of the Board, and settlement agreements with certain officers and directors contemplate about 1.9 USD million of aggregate payments upon the final closing.
Mainz Biomed N.V. disclosed that it has completed share sales under a prospectus supplement tied to its equity distribution agreement with Maxim Group LLC. From January 5, 2026 through January 23, 2026, the company sold 1,735,194 ordinary shares on Nasdaq, generating aggregate gross proceeds of $2,152,822.40 before commissions and expenses.
The prospectus supplement allowed sales of ordinary shares up to an aggregate maximum offering price of $2,152,823, which has now been fully utilized. The broader equity distribution agreement, which permits offerings of up to $10,000,000 of ordinary shares, remains available for future sales, subject to market conditions and other factors.